(NASDAQ:KTTA),(NASDAQ:KTTAW), MIAMI, Jan. 13, 2026 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation oral macrocyclic MEK inhibitor for the treatment of neurofibromatosis type 1 associated plexiform neurofibromas (NF1-PN), today provided updated timelines on its ongoing clinical trials in advanced cancer and adult NF1-PN […]

Latest smartwatch for mariners offers satellite and cellular connectivity for added peace of mind, enhanced boat mode and more Garmin (NYSE: GRMN) today announced quatix® 8 Pro, the ultimate nautical smartwatch equipped with inReach® technology for two-way satellite and cellular connectivity1 – giving mariners access to text messaging, voice calling, SOS capabilities and more without

Klein Civil Rights (Brett H. Klein, Esq., PLLC) has expanded into new offices at the landmark Woolworth Building, 233 Broadway, Suite 1720, New York, NY 10279. Founded by civil rights attorney Brett H. Klein, the firm is dedicated to protecting the rights of individuals in cases such as police and corrections brutality, false arrest, malicious

Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines GlobeNewswire January 13, 2026 MIAMI, Jan. 13, 2026 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation oral macrocyclic MEK inhibitor for the treatment of neurofibromatosis type 1 associated plexiform neurofibromas (NF1-PN),

Restaurant Brands International Inc. (“RBI”, “the company”) (NYSE: QSR) (TSX: QSR) (TSX: QSP) today announced key 2026 dates, including an upcoming Investor Event on February 26, 2026 and preliminary 2026 earnings call dates. February 26, 2026 Investor Event The company will host an Investor Event in Miami, Florida on February 26, 2026. The event will

DUBAI, United Arab Emirates, Jan. 13, 2026 (GLOBE NEWSWIRE) — The first months of 2026 have produced a renewed interest in early-stage cryptocurrencies tied to real protocol deployment. Among the new entrants gaining attention is Mutuum Finance (MUTM). The project reports rising activity as its next phase approaches, and traders are watching how the token

(NASDAQ:SOTK), Seventh Consecutive Quarter of Revenue Over $5 Million Driven by Continued Strength in Medical Market and High-ASP Production Systems Gross Margin Expands to 50% in the Quarter and 51% Year-to-Date Third Quarter and Nine-Month Net Income Increased 24% and 32% Respectively Backlog Reaches Record $12.3 Million Reflecting Continued Order Momentum Reiterates Full Year FY

Company Expands Its Innovative Portfolio to Accelerate Advances in Diagnostics Synthego, a recognized leader in CRISPR solutions, announces its formal entry into the molecular and clinical diagnostic reagents sector. Building upon its reputation for rigorous quality, custom manufacturing, and innovation, Synthego’s significant expansion of its product portfolio empowers researchers, clinicians, and diagnostic laboratories with high-quality,

(NASDAQ:OCGN), MALVERN, Pa., Jan. 13, 2026 (GLOBE NEWSWIRE) — Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast with KOLs and Ocugen executive leadership to discuss data from the first half of patients completing

(TSX:TDG), VANCOUVER, British Columbia, Jan. 13, 2026 (GLOBE NEWSWIRE) — TDG Gold Corp. (TSXV: TDG | OTCQX: TDGGF) (the “Company” or “TDG”) is pleased to report additional Phase I drilling results from the Aurora West Zone within TDG's Greater Shasta-Newberry (“GSN“) project located in the Toodoggone District of British Columbia. To date, the fully funded,